Mylan to pay equivlant of $757 million to buy Aspen’s Europe thrombosis business

/ / News

Mylan N.V. said Tuesday it will pay EUR641.9 million ($756.8 million) for Aspen Pharmacare Holdings Ltd.’s thrombosis business in Europe. The deal is expected to add to Mylan’s earnings immediately after closing, which is expected to be before Dec. 31.. Mylan expects to provide an upfront payment of EUR263.2 million to Aspen upon closing, funded from existing cash. Mylan’s stock, which is still inactive in premarket trading, has lost 21.3% year to date through Friday, while the S&P 500 has gained 6.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.